Northwest Compounding Pharmacy Recalls Lidocaine Gel Due to Sterility Concerns
Northwest Compounding Pharmacy is recalling Lidocaine gel 2% due to a lack of sterility assurance. The product was distributed in Oregon to medical facilities and patients.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. According to the rubric, FDA Class II recalls with potential for serious injury (such as infection from lack of sterility) are categorized as Severe.
Plain-English summary
Hiers Enterprises, LLC dba Northwest Compounding Pharmacy is recalling Lidocaine gel 2%, RX, plastic dropper, 125 ml. The recall is due to a lack of sterility assurance in the product.
The affected product was distributed exclusively in the state of Oregon to 3 medical facilities, 1 physician's office, and 80 consumers/patients. These are compounded products, meaning labels vary for each compound and are specific to each patient. The firm did not provide specific labeling details.
Consumers and medical facilities should stop using the recalled product and contact their healthcare provider or the pharmacy for further instructions.
The recalled product
- Product
- Lidocaine gel 2%, RX, plastic dropper
- Category
- Drug — Compounded Medication
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- 10222018@15
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 17 recalled by Hiers Enterprises, LLC dba Northwest Compounding Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 17 products in this recall →Related recalls
Same manufacturer · Hiers Enterprises, LLC dba Northwest Compounding Pharmacy
See all →- SevereNorthwest Compounding Pharmacy Recalls Lidocaine Gel 1% Due to Sterility Concerns
FDA (Drugs) · 2019-01-09
- SevereNorthwest Compounding Pharmacy Recalls Cyclosporin Liquid Due to Sterility Concerns
FDA (Drugs) · 2019-01-09
- SevereNorthwest Compounding Pharmacy Recalls Cyclosporin Liquid Due to Sterility Concerns
FDA (Drugs) · 2019-01-09
- SevereNorthwest Compounding Pharmacy Recalls Cyclosporin Liquid Due to Sterility Concerns
FDA (Drugs) · 2019-01-09
- SevereNorthwest Compounding Pharmacy Recalls Epinephrine Liquid Due to Sterility Concerns
FDA (Drugs) · 2019-01-09
Same hazard · lack of sterility
See all →- SevereK.C. Pharmaceuticals Recalls Dry Eye Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Multiple Brands of Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Assurance Issues
FDA (Drugs) · 2026-09-30
- SevereGentle Eyes Lubricant Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
Similar recalls
- SevereFDA Recalls Lidoaine HCL Solution Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-11-12
- SevereWestern Drug Recalls Lidocaine Injection Due to Sterility Concerns
FDA (Drugs) · 2015-12-09
- SevereRXQ Compounding Recalls Lidocaine HCL 2% Injection Due to Sterility Concerns
FDA (Drugs) · 2019-08-14
- SevereFDA Recalls Alprostadil/Lidocaine Vials Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-11-12
- SevereRXQ Compounding Recalls Lidocaine Injection Due to Sterility Concerns
FDA (Drugs) · 2019-08-14
- SevereLidocaine 4% Urethral Gel Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-03-12